Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-109 combination study in advanced solid tumors including Ewing sarcoma and colorectal cancer
NL-OMON60925Phase 2Recruiting
- Sponsor
- Inhibrx Biosciences
- Start
- Apr 2025
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of ozekibart in Ewing sarcoma, colorectal adenocarcinoma, Succinate Dehydrogenase-Deficient Neoplasms and 2 more, sponsored by Inhibrx Biosciences. Started Apr 2025; status: recruiting.
02
Drugs
ozekibart
03
Conditions
Ewing sarcomacolorectal adenocarcinomaSuccinate Dehydrogenase-Deficient Neoplasmsgastrointestinal stromal tumor (GIST)advanced nonhematological malignancy
Beyond the preview
Go deeper on NL-OMON60925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60925.